#ProphecyNewsWatch : When A #Tarot Reader Meets #Jesus

By PNW Staff
September 28, 2026

Alexandra Ashcroft built an enormous audience as “Alex Reads Tarot.”

Nearly one million #people followed her #online, where tarot wasn’t merely a private curiosity. It was her #platform, identity and #business.

Then something changed.

In June, Ashcroft wiped away her tarot content and #announced that she had become a #Christian.

” #JesusChrist has saved my life, and I can no longer ignore that reality,” she told her followers.
–

Breitbart : Trump – #Iran #War Will End Even if #GOP Loses Because People ‘Think if We Lose,’ I’ll Be Mad and ‘Just Take Care of #Business’

Ian Hanchett
11 Sep 2026

During an interview aired on Friday’s broadcast of the Fox News Channel’s “Ingraham Angle,” President Donald Trump defended his prediction that the Iran War will end after the 2026 midterm elections and responded to a question on why the war will end if #Republicans lose the #elections by saying that “a lot of people think if we lose, then I’ll be much more #angry and I’ll just take care of business, that’s another way of doing it.”

Host Laura Ingraham said that Canadian #PrimeMinister Mark Carney is “trying to wait out the #midterms as well, isn’t he?”

Trump responded, “I think a lot of people are. So, Iran’s — as soon as they’re — by the way, the war will end right after the midterms.”

Ingraham then asked, “If Republicans win. But if Republicans lose in the midterms, why would the Iran War end?”

Trump answered, “Well, I think a lot of people think if we lose, then I’ll be much more angry and I’ll just take care of business, that’s another way of doing it. Either way, they lose.”

#Global #Business Line : Future of #Human–#Technology Integration – #BrainImplant

Beyond #healthcare, #advancements in BCI technology could pave the way for new forms of human–machine interaction. However, regulatory, ethical, and societal #considerations will play a key role in shaping #adoption.
–

#Global #Business Line : #Healthcare and #Economic Impact – #BrainImplant

If successful, #brain– #computer interfaces could redefine treatment options for #neurological conditions. This would have #significant #implications for #healthcare systems, insurers, and patients, potentially reducing long-term care costs.
–

#Global #Business Line : Changing #Investor #Behaviour – #BrainImplant

#Investors are increasingly willing to fund long-term, capital-intensive ventures in #healthcare and deep tech. #Science Corp.’s progress reflects growing confidence in the potential of #neurotechnology to deliver transformative outcomes.
–

#Global #Business Line : Shift Toward #Clinical #Execution – #BrainImplant

The move to #human t highlights a broader industry #transition from #theoretical #research to real-world #application. This phase is critical for #validating both the #technology and its #commercial #viability.
–

#Global #Business Line : #Regional Market #Dynamics – #BrainImplant

The #US leads the #BCI sector due to strong venture capital support and #research #infrastructure. #Europe follows with a more regulated, research-driven approach, while #India remains in early stages, with limited startup activity in #neurotechnology.

#Global #Business Line : #Differentiation in Approach – #BrainImplant

While #Neuralink emphasises #ambitious long-term #capabilities, #Synchron prioritises near-term #clinical #viability. Science Corp. #positions itself between these strategies, aiming for scalable medical #applications with #manageable risk profiles.

#Global #Business Line : Key #Competitors in the US – #BrainImplant

#Science Corp. competes directly with #Neuralink, which is pursuing high-bandwidth #brain interfaces, and #Synchron, which focuses on minimally invasive #implantation techniques. Both companies have advanced into #human trials.
–

#Global #Business Line : #Platform #Strategy and #Scalability – #BrainImplant

Beyond a single product, the company is building a broader scientific platform. By investing in multiple #research areas such as #neuroprosthetics and #ophthalmology, it aims to diversify risk and expand its long-term #commercial #potential.
–